About Pacific Biosciences of California Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.pacb.com/
Frequently Asked Questions
What is the 52-week range for PACB?
The 52-week high is $2.73 and the 52-week low is $1.07.
What is the P/E ratio for PACB?
The P/E ratio data is currently unavailable.
What is the dividend yield for PACB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -488.45%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -82.49%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 105.55.
Analyst Recommendation Trends
Wall Street analyst consensus for PACB over the last few months:
Latest PACB News
PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In Focus
Preview next weekâs key market eventsâPMI, Fed minutes, jobless claimsâand top earnings (PepsiCo, Delta). Read here for more details.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
3 Biotech Stocks Put Traders Are Targeting Today
NKTR, QSI, and PACB are drawing attention from options bears
Pacific Biosciences: Stock Surges As New Use Case Seen - But Caution Is Warranted
Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like Illumina. Read why PACB stock is a buy.
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
Why Is PacBio (PACB) Stock Soaring Today
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the launch of EpiSign METRIC 5-base, enabling laboratories to analyze DNA methylation data on the company's HiFi sequencing platform.
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Discover the most active stocks in Wednesday's session.
Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of their
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Check out the companies making headlines yesterday:
Why PacBio (PACB) Stock Is Trading Up Today
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
1 Stock Under $10 with Exciting Potential and 2 We Avoid
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
2 Small-Cap Stocks for Long-Term Investors and 1 Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pacific Biosciences of California, Inc. (PACB) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:50 PM EDTCompany...
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be ava
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-17 | Van Oene Mark | -26,911 | $1.13 | $30,409 |
| 2026-08-10 | Van Oene Mark | +1,967,888 | - | - |
| 2026-08-10 | Van Oene Mark | +489,130 | - | - |
| 2026-06-03 | Gibson Christopher | +74,497 | - | - |
| 2026-06-03 | Smith Christopher M | +223,492 | - | - |
| 2026-06-03 | Valantine Hannah | +223,492 | - | - |
| 2026-06-03 | Ericson William W. | +223,492 | - | - |
| 2026-06-03 | MOHR MARSHALL | +223,492 | - | - |
| 2026-06-03 | LIVINGSTON RANDALL S | +223,492 | - | - |
| 2026-06-03 | ORDONEZ KATHY | +223,492 | - | - |
| 2026-06-03 | MILLIGAN JOHN F | +223,492 | - | - |
| 2026-04-08 | Gibson Christopher | +77,842 | - | - |
| 2026-04-08 | Gibson Christopher | +57,473 | - | - |
| 2026-04-01 | Gibson James R II | -88,185 | $1.37 | $120,813 |
| 2026-03-03 | Gibson Christopher | +73,087 | - | - |
| 2026-03-03 | Gibson Christopher | +53,913 | - | - |
| 2026-03-03 | Van Oene Mark | -6,504 | $1.514 | $9,847 |
| 2026-03-03 | Farmer Michele | -2,979 | $1.514 | $4,510 |
| 2026-03-03 | HENRY CHRISTIAN O | -12,497 | $1.514 | $18,920 |
| 2026-02-27 | Farmer Michele | +179,670 | - | - |
| 2026-02-27 | Farmer Michele | +89,835 | - | - |
| 2026-02-27 | Gibson James R II | +667,696 | - | - |
| 2026-02-27 | Gibson James R II | +333,848 | - | - |
| 2026-02-27 | Van Oene Mark | +1,000,000 | - | - |
| 2026-02-27 | Van Oene Mark | +500,000 | - | - |
| 2026-02-27 | HENRY CHRISTIAN O | +1,841,621 | - | - |
| 2026-02-27 | HENRY CHRISTIAN O | +920,810 | - | - |
| 2026-02-18 | Van Oene Mark | -55,107 | $1.629 | $89,769 |
| 2026-02-18 | Farmer Michele | -14,952 | $1.629 | $24,357 |
| 2026-02-18 | HENRY CHRISTIAN O | -140,874 | $1.629 | $229,484 |
| 2026-02-17 | Van Oene Mark | -129,790 | $1.576 | $204,549 |
| 2026-02-17 | Farmer Michele | -35,215 | $1.576 | $55,499 |
| 2026-02-17 | HENRY CHRISTIAN O | -331,793 | $1.576 | $522,906 |